In vivo inhibition of human CYP1A2 activity by oltiprazSOFOWORA, Gbemiga G; CHOO, Edna F; MAYO, Gail et al.Cancer chemotherapy and pharmacology. 2001, Vol 47, Num 6, pp 505-510, issn 0344-5704Article

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: Application to various assay techniquesKIM, Jooran S; NAFZIGER, Anne N; GREENBLATT, David J et al.Journal of clinical pharmacology. 2002, Vol 42, Num 4, pp 376-382, issn 0091-2700Article

Identification of functionally variant MDR1 alleles among European Americans and African AmericansKIM, Richard B; LEAKE, Brenda F; LAN, Lu-Bin et al.Clinical pharmacology and therapeutics. 2001, Vol 70, Num 2, pp 189-199, issn 0009-9236Article

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical ResponseWONG, Harvey; CHOO, Edna F; GOULD, Stephen E et al.Clinical cancer research (Print). 2012, Vol 18, Num 14, pp 3846-3855, issn 1078-0432, 10 p.Article

Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitorDIAZ, Dolores; FORD, Kevin A; SUTHERLIN, Daniel P et al.Toxicology and applied pharmacology. 2013, Vol 266, Num 1, pp 86-94, issn 0041-008X, 9 p.Article

Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3 -isopropyl -[1,2,4 ] -triazolo [4,3-a] pyridine, a novel and selective p38a inhibitor : Identification of an active metabolite in preclinical species and human liver microsomesKALGUTKAR, Amit S; HATCH, Heather L; LETAVIC, Michael A et al.Biopharmaceutics & drug disposition. 2006, Vol 27, Num 8, pp 371-386, issn 0142-2782, 16 p.Article

Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenograftsGONG, Inna Y; TEFT, Wendy A; LY, Justin et al.Breast cancer research and treatment. 2013, Vol 139, Num 1, pp 61-69, issn 0167-6806, 9 p.Article

Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam: Midazolam do not predict midazolam clearance in healthy subjectsROGERS, Janyce F; NAFZIGER, Anne N; KASHUBA, Angela D. M et al.Journal of clinical pharmacology. 2002, Vol 42, Num 10, pp 1079-1082, issn 0091-2700, 4 p.Article

PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenograftsCHOO, Edna F; NG, Chee M; BERRY, Leanne et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 1, pp 133-143, issn 0344-5704, 11 p.Article

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK InhibitorWONG, Harvey; VERNILLET, Laurent; HOEFLICH, Klaus P et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3090-3099, issn 1078-0432, 10 p.Article

Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+ ) -2 -[4 -({[2 -(benzo[1,3 ]dioxol -5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and humanKALGUTKAR, Amit S; BO FENG; DUIGNAN, David B et al.Drug metabolism and disposition. 2007, Vol 35, Num 11, pp 2111-2118, issn 0090-9556, 8 p.Article